PYPDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

PolyPid Ltd.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Feb 25, 2026

$4.88+0.16 (+3.39%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): 2.3
Dividend yield: –

Earnings

Quarterly results announced on Form 8-K, Item 2.02

Quarter	Reported	Time	Revenue	EPS (GAAP)	EPS (adjusted)
Q2 FY2026 Ended Jun 30, 2026	Aug 12, 2026	Before market open	–	$-0.35	–
Q4 FY2025 Ended Dec 31, 2025	Feb 11, 2026	Before market open	–	$-0.41	–
Q2 FY2025 Ended Jun 30, 2025	Aug 13, 2025	Before market open	–	$-0.78	–
Q4 FY2024 Ended Dec 31, 2024	Feb 12, 2025	Before market open	–	$-1.13	–
Q2 FY2024 Ended Jun 30, 2024	Aug 14, 2024	Before market open	–	$-1.25	–
Q4 FY2023 Ended Dec 31, 2023	Feb 14, 2024	Before market open	–	$-3.97	–
Q2 FY2023 Ended Jun 30, 2023	Aug 9, 2023	Before market open	–	$-0.13	–
Q4 FY2022 Ended Dec 31, 2022	Feb 8, 2023	Before market open	–	–	–
Q2 FY2022 Ended Jun 30, 2022	Aug 10, 2022	Before market open	–	–	–
Q4 FY2021 Ended Dec 31, 2021	Feb 9, 2022	Before market open	–	–	–

Press releases

Announcements PolyPid filed with the SEC

Oct 1, 2026, 9:20 AM ET
PRESS RELEASE ISSUED BY POLYPID LTD. ON OCTOBER 1, 2026, TITLED "EUROPEAN MEDICINES AGENCY VALIDATES POLYPID'S MARKETING AUTHORIZATION APPLICATION FOR D-PLEX100."
EX-99.1 to Form 6-K
Oct 1, 2026, 9:00 AM ET
PRESS RELEASE ISSUED BY POLYPID LTD. ON OCTOBER 1, 2026, TITLED "POLYPID REGAINS EUROPEAN COMMERCIALIZATION RIGHTS FOR D-PLEX100 EXPANDING GLOBAL COMMERCIALIZATION OPPORTUNITIES."
EX-99.1 to Form 6-K
Aug 12, 2026, 4:58 PM ET
POLYPID LTD. AND ITS SUBSIDIARIES
EX-99.1 to Form 6-K
Aug 12, 2026, 4:58 PM ET
POLYPID LTD.'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION FOR THE SIX MONTHS ENDED JUNE 30, 2026
EX-99.2 to Form 6-K
Aug 12, 2026, 7:35 AM ET
PRESS RELEASE ISSUED BY POLYPID LTD. ON AUGUST 12, 2026, TITLED "POLYPID PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS."
EX-99.1 to Form 6-K
Jul 29, 2026, 8:35 AM ET
PRESS RELEASE ISSUED BY POLYPID LTD. ON JULY 29, 2026, TITLED "POLYPID ANNOUNCES FDA ACCEPTANCE OF NDA WITH PRIORITY REVIEW FOR D-PLEX100."
EX-99.1 to Form 6-K
Jul 21, 2026, 7:35 AM ET
PRESS RELEASE ISSUED BY POLYPID LTD. ON JULY 21, 2026, TITLED "POLYPID ANNOUNCES EXCLUSIVE PARTNERSHIP WITH AZURITY PHARMACEUTICALS FOR THE COMMERCIALIZATION OF D-PLEX100 IN THE U.S. AND CANADA."
EX-99.1 to Form 6-K
Jul 15, 2026, 4:01 PM ET
AMENDED AND RESTATED 2012 SHARE OPTION PLAN
EX-99.1 to Form 6-K
Jun 10, 2026, 4:01 PM ET
NOTICE FOR THE ANNUAL AND EXTRAORDINARY GENERAL MEETING TO BE HELD ON JULY 15, 2026
EX-99.1 to Form 6-K
Jun 10, 2026, 4:01 PM ET
PROXY STATEMENT FOR THE ANNUAL AND EXTRAORDINARY GENERAL MEETING TO BE HELD ON JULY 15, 2026
EX-99.2 to Form 6-K
Jun 10, 2026, 4:01 PM ET
PROXY CARD FOR THE ANNUAL AND EXTRAORDINARY GENERAL MEETING TO BE HELD ON JULY 15, 2026
EX-99.3 to Form 6-K
Jun 1, 2026, 8:35 AM ET
PRESS RELEASE ISSUED BY POLYPID LTD. ON JUNE 1, 2026, TITLED "POLYPID COMPLETES NEW DRUG APPLICATION SUBMISSION TO FDA FOR D-PLEX100"
EX-99.1 to Form 6-K
May 13, 2026, 7:35 AM ET
PRESS RELEASE ISSUED BY POLYPID LTD. ON MAY 13, 2026, TITLED "POLYPID PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS."
EX-99.1 to Form 6-K
Mar 31, 2026, 8:35 AM ET
PRESS RELEASE ISSUED BY POLYPID LTD. ON MARCH 31, 2026, TITLED "POLYPID INITIATES D-PLEX100 NDA SUBMISSION TO THE FDA."
EX-99.1 to Form 6-K
Feb 11, 2026, 7:35 AM ET
PRESS RELEASE ISSUED BY POLYPID LTD. ON FEBRUARY 11, 2026, TITLED "POLYPID PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2025 FINANCIAL RESULTS."
EX-99.1 to Form 6-K
Dec 31, 2025, 4:01 PM ET
NOTICE FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON FEBRUARY 4, 2026
EX-99.1 to Form 6-K
Dec 31, 2025, 4:01 PM ET
PROXY STATEMENT FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON FEBRUARY 4, 2026
EX-99.2 to Form 6-K
Dec 31, 2025, 4:01 PM ET
PROXY CARD FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON FEBRUARY 4, 2026
EX-99.3 to Form 6-K
Dec 16, 2025, 8:35 AM ET
PRESS RELEASE ISSUED BY POLYPID LTD. ON DECEMBER 16, 2025, TITLED "POLYPID APPOINTS VETERAN MEDTECH LEADER BROOKE STORY AS CHAIRMAN OF THE BOARD OF DIRECTORS."
EX-99.1 to Form 6-K
Dec 3, 2025, 8:35 AM ET
PRESS RELEASE ISSUED BY POLYPID LTD. ON DECEMBER 3, 2025, TITLED "POLYPID ANNOUNCES POSITIVE FDA PRE-NDA MEETING MINUTES FOR D-PLEX100 SUPPORTING NDA SUBMISSION."
EX-99.1 to Form 6-K
Nov 12, 2025, 7:38 AM ET
PRESS RELEASE ISSUED BY POLYPID LTD. ON NOVEMBER 12, 2025, TITLED "POLYPID PROVIDES CORPORATE UPDATE AND REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS."
EX-99.1 to Form 6-K
Sep 16, 2025, 8:36 AM ET
PRESS RELEASE ISSUED BY POLYPID LTD. ON SEPTEMBER 16, 2025, TITLED "POLYPID SUCCESSFULLY COMPLETES ISRAELI MINISTRY OF HEALTH GMP INSPECTION, ADVANCING TOWARDS COMMERCIAL MANUFACTURING READINESS FOR D-PLEX100."
EX-99.1 to Form 6-K
Aug 13, 2025, 5:06 PM ET
AS OF JUNE 30, 2025
EX-99.1 to Form 6-K
Aug 13, 2025, 5:06 PM ET
POLYPID LTD.'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION FOR THE SIX MONTHS ENDED JUNE 30, 2025
EX-99.2 to Form 6-K
Aug 13, 2025, 7:35 AM ET
PRESS RELEASE ISSUED BY POLYPID LTD. ON AUGUST 13, 2025, TITLED "POLYPID PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS."
EX-99.1 to Form 6-K
Aug 12, 2025, 8:05 AM ET
PRESS RELEASE ISSUED BY POLYPID LTD. ON AUGUST 12, 2025, TITLED "POLYPID APPOINTS DR. NURIT TWEEZER-ZAKS AS CHIEF MEDICAL OFFICER."
EX-99.1 to Form 6-K
Jul 15, 2025, 9:00 AM ET
PRESS RELEASE ISSUED BY POLYPID LTD. ON JULY 15, 2025, TITLED "POLYPID UNVEILS A LONG-ACTING GLP-1 RECEPTOR AGONISTS DELIVERY PLATFORM TARGETING THE DIABETES AND WEIGHT LOSS MARKET."
EX-99.1 to Form 6-K
Jun 25, 2025, 4:05 PM ET
Compensation Policy for Officers and Directors
EX-99.1 to Form 6-K
Jun 17, 2025, 8:38 AM ET
PRESS RELEASE ISSUED BY POLYPID LTD. ON JUNE 16, 2025, TITLED "POLYPID SECURES $26.7 MILLION THROUGH WARRANT EXERCISE FOLLOWING SUCCESSFUL SHIELD II PHASE 3 TRIAL RESULTS"
EX-99.1 to Form 6-K
Jun 9, 2025, 7:35 AM ET
PRESS RELEASE ISSUED BY POLYPID LTD. ON JUNE 9, 2025, TITLED "POLYPID ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 SHIELD II TRIAL: D-PLEX100 DEMONSTRATED SIGNIFICANT REDUCTION IN SURGICAL SITE INFECTIONS AND SUCCESSFULLY
EX-99.1 to Form 6-K
May 30, 2025, 4:05 PM ET
AMENDED AND RESTATED 2012 SHARE OPTION PLAN
EX-99.1 to Form 6-K
May 21, 2025, 4:05 PM ET
NOTICE FOR THE ANNUAL AND EXTRAORDINARY GENERAL MEETING TO BE HELD ON JUNE 25, 2025
EX-99.1 to Form 6-K
May 21, 2025, 4:05 PM ET
PROXY STATEMENT FOR THE ANNUAL AND EXTRAORDINARY GENERAL MEETING TO BE HELD ON JUNE 25, 2025
EX-99.2 to Form 6-K
May 21, 2025, 4:05 PM ET
PROXY CARD FOR THE ANNUAL AND EXTRAORDINARY GENERAL MEETING TO BE HELD ON JUNE 25, 2025
EX-99.3 to Form 6-K
May 14, 2025, 7:13 AM ET
PRESS RELEASE ISSUED BY POLYPID LTD. ON MAY 14, 2025, TITLED "POLYPID PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS."
EX-99.1 to Form 6-K
Mar 11, 2025, 7:05 AM ET
PRESS RELEASE ISSUED BY POLYPID LTD. ON MARCH 11, 2025, TITLED "POLYPID ANNOUNCES SUCCESSFUL COMPLETION OF ENROLLMENT IN PHASE 3 SHIELD II TRIAL OF D-PLEX100 FOR THE PREVENTION OF ABDOMINAL COLORECTAL SURGICAL SITE INFECTIONS."
EX-99.1 to Form 6-K
Feb 12, 2025, 7:05 AM ET
PRESS RELEASE ISSUED BY POLYPID LTD. ON FEBRUARY 12, 2025, TITLED "POLYPID PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS"
EX-99.1 to Form 6-K
Dec 26, 2024, 10:15 AM ET
PolyPid Announces Positive Recommendation by
EX-99.1 to Form 6-K
Dec 26, 2024, 10:15 AM ET
FORM OF SECURITIES PURCHASE AGREEMENT BETWEEN POLYPID LTD. AND THE INVESTORS NAMED THEREIN, DATED DECEMBER 23, 2024
EX-99.2 to Form 6-K
Dec 26, 2024, 10:15 AM ET
FORM OF REGISTRATION RIGHTS AGREEMENT BETWEEN POLYPID LTD. AND THE INVESTORS NAMED THEREIN, DATED DECEMBER 23, 2024
EX-99.3 to Form 6-K